The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

GLP-1 weight-loss drugs are cutting calories… and grocery bills, according to a new study from Cornell and Numerator.

Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...

I applaud the Biden administration’s recent moves to make these anti-obesity drugs more accessible to people on Medicaid and ...

TV star and comedian Katherine Ryan has responded to claims from her teenage daughter that she has been using controversial ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

From heart and kidney health to addiction reduction, GLP-1 drugs like Ozempic and Mounjaro may help with more than just ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Health Care Health Care   The Big Story MAHA leaders heading for clash over GLP-1 drugs Two of President-elect Trump’s top ...

Billionaire entrepreneur and top adviser to President-elect Donald Trump, Elon Musk, touted that he has reaped the benefits of Ozempic after fellow top Trump adviser, Robert F. Kennedy Jr., suggested ...

Taking a glp-1 medication for weight loss isn't appropriate for everyone. There are side effects and costs to consider.

Two of President-elect Trump’s top health nominees are on a collision course as the incoming administration faces a crucial ...